|
1
|
Razumilava N and Gores GJ:
Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Razumilava N and Gores GJ: Combination of
gemcitabine and cisplatin for biliary tract cancer: A platform to
build on. J Hepatol. 54:577–578. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Esnaola NF, Meyer JE, Karachristos A,
Maranki JL, Camp ER and Denlinger CS: Evaluation and management of
intrahepatic and extrahepatic cholangiocarcinoma. Cancer.
122:1349–1369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Charbel H and Al-Kawas FH:
Cholangiocarcinoma: Epidemiology, risk factors, pathogenesis, and
diagnosis. Curr Gastroenterol Rep. 13:182–187. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khan SA, Davidson BR, Goldin RD, Heaton N,
Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD,
Thillainayagam AV, et al: Guidelines for the diagnosis and
treatment of cholangiocarcinoma: An update. Gut. 61:1657–1669.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Everhart JE and Ruhl CE: Burden of
digestive diseases in the United States Part III: Liver, biliary
tract, and pancreas. Gastroenterology. 136:1134–1144. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tyson GL and El-Serag HB: Risk factors for
cholangiocarcinoma. Hepatology. 54:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen C, Nelson LJ, Avila MA and Cubero FJ:
Mitogen-activated protein kinases (MAPKs) and cholangiocarcinoma:
The Missing Link. Cells. 8:11722019. View Article : Google Scholar
|
|
9
|
Blechacz B, Komuta M, Roskams T and Gores
GJ: Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev
Gastroenterol Hepatol. 8:512–522. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bridgewater J, Galle PR, Khan SA, Llovet
JM, Park JW, Patel T, Pawlik TM and Gores GJ: Guidelines for the
diagnosis and management of intrahepatic cholangiocarcinoma. J
Hepatol. 60:1268–1289. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang H, Yang T, Wu M and Shen F:
Intrahepatic cholangiocarcinoma: Epidemiology, risk factors,
diagnosis and surgical management. Cancer Lett. 379:198–205. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moeini A, Sia D, Bardeesy N, Mazzaferro V
and Llovet JM: Molecular pathogenesis and targeted therapies for
intrahepatic Cholangiocarcinoma. Clin Cancer Res. 22:291–300. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fornari FA, Randolph JK, Yalowich JC,
Ritke MK and Gewirtz DA: Interference by doxorubicin with DNA
unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 45:649–656.
1994.PubMed/NCBI
|
|
15
|
Momparler RL, Karon M, Siegel SE and Avila
F: Effect of adriamycin on DNA, RNA, and protein synthesis in
cell-free systems and intact cells. Cancer Res. 36:2891–2895.
1976.PubMed/NCBI
|
|
16
|
QuanJun Y, GenJin Y, LiLi W, YongLong H,
Yan H, Jie L, JinLu H, Jin L, Run G and Cheng G: Protective effects
of dexrazoxane against doxorubicin-induced cardiotoxicity: A
metabolomic study. PLoS One. 12:e01695672017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Theodoulou M and Hudis C: Cardiac profiles
of liposomal anthracyclines: Greater cardiac safety versus
conventional doxorubicin? Cancer. 100:2052–2063. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshino Y and Ishioka C: Inhibition of
glycogen synthase kinase-3 beta induces apoptosis and mitotic
catastrophe by disrupting centrosome regulation in cancer cells.
Sci Rep. 5:132492015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fang G, Zhang P, Liu J, Zhang X, Zhu X, Li
R and Wang H: Inhibition of GSK-3β activity suppresses HCC
malignant phenotype by inhibiting glycolysis via activating
AMPK/mTOR signaling. Cancer Lett. 463:11–26. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dai R, Chen R and Li H: Cross-talk between
PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum
stress-induced cell cycle progression and cell death in human
hepatocellular carcinoma cells. Int J Oncol. 34:1749–1757.
2009.PubMed/NCBI
|
|
21
|
Sun M, Wang G, Paciga JE, Feldman RI, Yuan
ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV and Cheng
JQ: AKT1/PKBalpha kinase is frequently elevated in human cancers
and its constitutive activation is required for oncogenic
transformation in NIH3T3 cells. Am J Pathol. 159:431–437. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Polivka J Jr and Janku F: Molecular
targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol
Ther. 142:164–175. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guerrero-Zotano A, Mayer IA and Arteaga
CL: PI3K/AKT/mTOR: Role in breast cancer progression, drug
resistance, and treatment. Cancer Metastasis Rev. 35:515–524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Edderkaoui M, Chheda C, Soufi B, Zayou F,
Hu RW, Ramanujan VK, Pan X, Boros LG, Tajbakhsh J, Madhav A, et al:
An Inhibitor of GSK3B and HDACs kills pancreatic cancer cells and
slows pancreatic tumor growth and metastasis in mice.
Gastroenterology. 155:1985–1998.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen W, Taylor B, Jin Q, Nguyen-Tran V,
Meeusen S, Zhang YQ, Kamireddy A, Swafford A, Powers AF, Walker J,
et al: Inhibition of DYRK1A and GSK3B induces human β-cell
proliferation. Nat Commun. 6:83722015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shang N, Arteaga M, Zaidi A, Stauffer J,
Cotler SJ, Zeleznik-Le NJ, Zhang J and Qiu W: FAK is required for
c-Met/β-catenin-driven hepatocarcinogenesis. Hepatology.
61:214–226. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Levy A, Alhazzani K, Dondapati P, Alaseem
A, Cheema K, Thallapureddy K, Kaur P, Alobid S and Rathinavelu A:
Focal adhesion kinase in ovarian cancer: A potential therapeutic
target for platinum and taxane-resistant tumors. Curr Cancer Drug
Targets. 19:179–188. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sulzmaier FJ, Jean C and Schlaepfer DD:
FAK in cancer: Mechanistic findings and clinical applications. Nat
Rev Cancer. 14:598–610. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Speth PA, van Hoesel QG and Haanen C:
Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet.
15:15–31. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rivankar S: An overview of doxorubicin
formulations in cancer therapy. J Cancer Res Ther. 10:853–858.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Genovese I, Fiorillo A, Ilari A,
Masciarelli S, Fazi F and Colotti G: Binding of doxorubicin to
Sorcin impairs cell death and increases drug resistance in cancer
cells. Cell Death Dis. 8:e29502017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao C, Holscher C, Liu Y and Li L: GSK3: A
key target for the development of novel treatments for type 2
diabetes mellitus and Alzheimer disease. Rev Neurosci. 23:1–11.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Juhaszova M, Zorov DB, Yaniv Y, Nuss HB,
Wang S and Sollott SJ: Role of glycogen synthase kinase-3beta in
cardioprotection. Circ Res. 104:1240–1252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu Y, Hu D, Qiu J, Xie X, Ye F and Lu WG:
Overexpression of glycogen synthase kinase-3 in ovarian carcinoma
cells with acquired paclitaxel resistance. Int J Gynecol Cancer.
21:439–444. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kawazoe H, Bilim VN, Ugolkov AV, Yuuki K,
Naito S, Nagaoka A, Kato T and Tomita Y: GSK-3 inhibition in vitro
and in vivo enhances antitumor effect of sorafenib in renal cell
carcinoma (RCC). Biochem Biophys Res Commun. 423:490–495. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Szymonowicz K, Oeck S, Malewicz NM and
Jendrossek V: New insights into protein kinase B/Akt signaling:
Role of localized akt activation and compartment-specific target
proteins for the cellular radiation response. Cancers (Basel).
10:782018. View Article : Google Scholar
|
|
38
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells and promotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
|
39
|
Kilic U, Caglayan AB, Beker MC, Gunal MY,
Caglayan B, Yalcin E, Kelestemur T, Gundogdu RZ, Yulug B, Yılmaz B,
et al: Particular phosphorylation of PI3K/Akt on Thr308 via PDK-1
and PTEN mediates melatonin's neuroprotective activity after focal
cerebral ischemia in mice. Redox Biol. 12:657–665. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bellacosa A, Chan TO, Ahmed NN, Datta K,
Malstrom S, Stokoe D, McCormick F, Feng J and Tsichlis P: Akt
activation by growth factors is a multiple-step process: The role
of the PH domain. Oncogene. 17:313–325. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang G, Murashige DS, Humphrey SJ and
James DE: A Positive Feedback Loop between Akt and mTORC2 via SIN1
Phosphorylation. Cell Rep. 12:937–943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sarbassov DD: mTOR-rictor Phosphorylation
and Regulation of Akt/PKB by the Rictor-mTOR Complex. Science.
307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen CH, Shaikenov T, Peterson TR,
Aimbetov R, Bissenbaev AK, Lee SW, Wu J, Lin HK and Sarbassov dos
D: ER stress inhibits mTORC2 and Akt signaling through
GSK-3β-mediated phosphorylation of rictor. Sci Signal. 4:ra102011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang S and Basson MD: Protein kinase B/AKT
and focal adhesion kinase: Two close signaling partners in cancer.
Anticancer Agents Med Chem. 11:993–1002. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Paul R, Luo M, Mo X, Lu J, Yeo SK and Guan
JL: FAK activates AKT-mTOR signaling to promote the growth and
progression of MMTV-Wnt1-driven basal-like mammary tumors. Breast
Cancer Res. 22:592020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Casar B, Rimann I, Kato H, Shattil SJ,
Quigley JP and Deryugina EI: In vivo cleaved CDCP1 promotes early
tumor dissemination via complexing with activated beta1 integrin
and induction of FAK/PI3K/Akt motility signaling. Oncogene.
33:255–268. 2014. View Article : Google Scholar : PubMed/NCBI
|
